The clinical trial results of India’s first CAR T-cell therapy, published in The Lancet, show that it worked for nearly 73 ...

Q4 2024 Earnings Call Transcript March 13, 2025 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Results from the company’s Phase I/II trial showed the injectable therapy to have an effective half-life of 91.4 hours.

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line (1L) Consolidation in ...

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 Signals of dose-dependent reduction in active reservoir, and viral ...

The planned registrational Phase 3 study of eRapa in FAP will be a double-blind placebo-controlled trial in 168 patients ... Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more ...

Incannex Healthcare Inc. (Nasdaq: IXHL) announced that it has raised $12.5 million to fund ongoing clinical trials. Incannex ...